Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page
- Check6 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.3.1. This appears to be a site revision update and does not alter the study details.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1, representing a minor template/version update with no changes to core study information or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRemoved a site-wide notice about potential delays and updates due to a lapse in government funding; the trial content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check35 days agoChange DetectedOnly minor visual/UI adjustments and timestamp updates were observed; the core study details remain unchanged (To avoid being alerted by small changes, set an alert condition by clicking below).SummaryDifference0.5%

- Check64 days agoChange DetectedOverall, the page updates to announce a system status notice and a new software version (v3.2.0), removing the previous v3.1.0 reference.SummaryDifference3%

- Check71 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The core page content shifts to the newer release identifier; no other substantive content changes are indicated.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.